“Similar” Biologics Could Use One Clinical Trial For All Indications – Teva
Executive Summary
Abbreviated applications for "similar" follow-on biologics could include clinical data in one indication to support approval in all innovator indications, Teva Senior Director Global Clinical Research Yafit Stark, PhD, said
You may also be interested in...
Follow-On Proteins May Present Problem For Post-Marketing Surveillance
Post-marketing surveillance may prove ineffective in detecting emerging safety issues for follow-on proteins, participants suggested at the FDA/Drug Information Association Scientific Workshop on Follow-on Protein Pharmaceuticals
Follow-On Proteins May Present Problem For Post-Marketing Surveillance
Post-marketing surveillance may prove ineffective in detecting emerging safety issues for follow-on proteins, participants suggested at the FDA/Drug Information Association Scientific Workshop on Follow-on Protein Pharmaceuticals
BIO “Follow-On” Biologics Risk-Based Proposal Would Require Clinical Tests
The Biotechnology Industry Organization's risk-based approach to a regulatory pathway for "follow-on" biologics would include a clinical testing requirement